Roche Feels Lucentis Market Could Move On Before Biosimilars Debut
Two New Ophthalmology Products Will Challenge Biosimilars, Roche Believes
Roche upended expectations for biosimilar Lucentis (ranibizumab) in the US, with a recent licensing deal signed with biosimilar sponsor Samsung Bioepis keeping the first proposed rival from the market until June 2022. The originator is also confident its pipeline assets will stem competition.
